Ovid Phe News Today

The EEOC’s revisions focus on lawful inquiries and examinations, confidentiality requirements, and reasonable accommodations based on disability, including Long COVID, or religious beliefs: Employer Inquiries, Employee Temperature Readings, Isolation, vaccine mandates

EEOC addresses questions through an update to its COVID-19 technical assistance explaining whether employers need to continue to provide accommodations for high risk individuals with disabilities; long covid, Reminder on Harassment and Discrimination and screenings measures

DEA issued a temporary rule that extends pandemic-era flexibilities allowing prescribing of controlled substances based on a telehealth relationship through November 11, 2023. It remains to be seen how the DEA will address inclusion or exclusion of Schedule II controlled substances.

The Drug Enforcement Agency released Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. They have extended COVID-19 waivers for prescribing controlled substances via telemedicine until November 11, 2023.

With the COVID-19 Public Health Emergency ending May 11, 2023, the DOL, Treasury, and HHS have published FAQs explaining how the end of the PHE will affect group health plans. The PHE will affect mandated coverage relating to COVID19 and employers should review their plans.

President Biden signed legislation passed by Congress ending COVID 19 National Emergency. Legislation has immediate effect National Emergency ends one full month prior to May 11 2023 date that Biden Administration and HHS previously announced to jointly end PHE and NE

The Biden Administration announced its intent to end the COVID 19 public health emergency on May 11, 2023. The PHE has been in place for over 3 years during which time many telehealth and other health care related flexibilities were relied upon by both patients and clinicians.